AI Pharma Leader XtalPi Raises $400M, Valued at $2B
AI pharmaceutical company XtalPi has raised USD 400 million in its Series D financing round, bringing its valuation to over RMB 13 billion (USD 2 billion). The round was led by OrbiMed and RRJ, with participation from Sequoia Capital, Sino Biopharmaceutical, and 5Y Capital. This significant funding comes less than a year after XtalPi's Series C round, which raised USD 300 million. The company has seen rapid growth, attracting prominent investors such as OrbiMed and RRJ. Alongside these main investors, several pharmaceutical companies also participated in the Series D round, although their names were not explicitly stated. With this latest round of funding, XtalPi continues to solidify its position as a leader in AI-driven pharmaceutical research. The company aims to use these funds to further develop its technology and expand its operations.
Read also:
- Elon Musk accused by Sam Altman of exploiting X for personal gain
- China's Automotive Landscape: Toyota's Innovative Strategy in Self-Driving Vehicles
- L3Harris' RASOR Revolutionizes Military Communications with Secure Satellite Broadband
- EU Bolsters Defense Capabilities: Orbotix Secures €6.5M for AI-Driven Drones
